TCR2 Therapeutics downgraded by Goldman with a new price target

1/19/22 7:24:24 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Goldman downgraded TCR2 Therapeutics from Buy to Neutral and set a new price target of $5.00 from $28.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TCRR

Date	Price Target	Rating	Analyst
1/19/2022	$28.00 → $5.00	Buy → Neutral	Goldman
1/13/2022	$25.00 → $19.00	Buy	HC Wainwright & Co.
11/19/2021	$55.00 → $26.00	Overweight	Piper Sandler
11/10/2021	$8.00 → $7.00	Market Perform	SVB Leerink
10/21/2021	$18.00 → $8.00	Outperform → Mkt Perform	SVB Leerink
9/20/2021	$40.00 → $29.00	Buy	Truist Securities
9/20/2021	$37.00 → $25.00	Buy	HC Wainwright & Co.
9/17/2021	$45.00 → $11.00	Outperform → Neutral	Wedbush